Press releases
Filter by year
- Jan 18, 2023Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment O…
- Nov 14, 2022Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season
- Oct 27, 2022Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Ta…
- Sep 08, 2022Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Present…
- Sep 07, 2022Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)
- Jul 13, 2022The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighte…
- Jul 07, 2022Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
- Jul 05, 2022Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of…
- May 15, 2022Urovant Sciences® presents new data from EMPOWUR study, advancing knowledge of the treatment of overactive bladder at the 2022 Ame…
- May 13, 2022Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tol…
- Apr 19, 2022Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® (Vibegron) 75mg in…
- Apr 13, 2022Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data fr…
- Apr 04, 2022Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer
- Mar 22, 2022Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladd…
- Mar 07, 2022Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
- Dec 20, 2021Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Sy…
- Nov 08, 2021Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTES…
- Oct 18, 2021Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion
- Sep 13, 2021Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was…
- Sep 03, 2021Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bla…
- Aug 18, 2021Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bla…
- Aug 12, 2021Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer
- Jul 06, 2021Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
- Jun 29, 2021Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive…
- Apr 15, 2021Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Blad…
- Apr 12, 2021Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
- Feb 12, 2021Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
- Feb 11, 2021Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monito…
- Dec 23, 2020Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bl…
- Nov 24, 2020Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain D…
- Nov 19, 2020Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
- Nov 12, 2020Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
- Nov 10, 2020Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
- Nov 02, 2020Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
- Oct 27, 2020Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
- Oct 07, 2020Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
- Sep 08, 2020Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference
- Aug 13, 2020Urovant Sciences Reports Fiscal First Quarter 2020 Results
- Aug 06, 2020Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
- Jun 18, 2020Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
- Jun 18, 2020Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
- Jun 11, 2020Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results
- Jun 02, 2020Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market…
- May 27, 2020Urovant Sciences Appoints James Hindman to Board of Directors
- May 26, 2020Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
- May 14, 2020Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urologi…
- Mar 23, 2020Urovant Sciences Appoints James Robinson as President and Chief Executive Officer
- Mar 05, 2020Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
- Mar 02, 2020Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology
- Feb 25, 2020Urovant Sciences to Present at Cowen and Company’s 40th Annual Health Care Conference
- Feb 13, 2020Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results
- Feb 06, 2020Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results
- Feb 04, 2020Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Ov…
- Jan 17, 2020Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell
- Jan 08, 2020Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
- Dec 30, 2019Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
- Dec 30, 2019Urovant Sciences Enters into $300 Million Term Loan Agreement with Sumitomo Dainippon Pharma
- Dec 30, 2019Urovant Sciences Majority Shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Complete Transaction for Strategic Alliance
- Dec 23, 2019Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902
- Nov 05, 2019Urovant Sciences Reports 2019 Second Fiscal Quarter Financial Results
- Oct 31, 2019Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections…
- Oct 29, 2019Urovant Sciences to Report 2019 Second Fiscal Quarter Financial Results
- Oct 21, 2019Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperpl…
- Sep 24, 2019Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patie…
- Sep 06, 2019Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Creat…
- Aug 13, 2019Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results
- Aug 06, 2019Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results
- Jun 13, 2019Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
- Jun 06, 2019Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
- Jun 03, 2019Urovant Sciences to Present at Annual Roivant Pipeline Day
- May 30, 2019Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference
- May 06, 2019Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meet…
- Apr 29, 2019Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Me…
- Mar 27, 2019Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
- Mar 19, 2019Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bla…
- Mar 18, 2019Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
- Mar 07, 2019Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
- Mar 06, 2019Urovant Sciences Appoints James Robinson to its Board of Directors
- Feb 22, 2019Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
- Feb 13, 2019Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
- Feb 06, 2019Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
- Jan 15, 2019Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019
- Jan 03, 2019Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irrit…
- Jan 02, 2019Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
- Dec 19, 2018Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference
- Nov 19, 2018Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference
- Nov 12, 2018Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
- Nov 08, 2018Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
- Nov 05, 2018Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results
- Nov 01, 2018Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology
- Sep 26, 2018Urovant Sciences Ltd. Announces Pricing of Initial Public Offering
- Sep 24, 2018Kyorin Receives Approval from Japan’s Ministry of Health, Labour and Welfare for Vibegron for Overactive Bladder
- Aug 28, 2018Urovant Sciences Licenses Novel Gene Therapy for Overactive Bladder
- Jul 09, 2018Urovant Sciences Appoints Sef Kurstjens and Pierre Legault to its Board of Directors
- Apr 24, 2018Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
- Mar 28, 2018Urovant Sciences Initiates Phase 3 Clinical Program for Vibegron in Patients with Overactive Bladder
- Feb 28, 2018Urovant Sciences Announces Upcoming Presentations of Data from Phase 2b Trial of Vibegron in Patients with Overactive Bladder
- Sep 18, 2017Urovant Sciences Appoints Keith A. Katkin as CEO
- Jun 06, 2017Roivant Sciences Launches Urovant to Develop Innovative Therapies in Urology